CACUL1/CAC1 attenuates p53 activity through PML post-translational modification

Biochem Biophys Res Commun. 2017 Jan 22;482(4):863-869. doi: 10.1016/j.bbrc.2016.11.125. Epub 2016 Nov 23.

Abstract

Promyelocytic leukaemia (PML) is a tumor suppressor protein covalently conjugated with SUMO family proteins, leading to the formation of PML nuclear bodies (NBs). PML-NBs provide a platform for efficient posttranslational modification of targets and protein-protein interaction, contributing to the adjustment of gene expression and chromatin integrity. Although PML SUMOylation is thought to play important roles in diverse cellular functions, the control mechanisms of adequate modification levels have remained unsolved. Here, we report that Cullin-related protein CACUL1/CAC1 (CACUL1) inhibits PML posttranslational modification. CACUL1 interacts with PML and suppresses PML SUMOylation, leading to the regulation of PML-NB size in the nucleus. We also found that Ubc9, a SUMO-conjugating enzyme, binds to CACUL1 and antagonizes the interaction between CACUL1 and PML. Furthermore, CACUL1 attenuates p53 transcriptional activity. These data suggest that CACUL1 is a novel regulator that negatively controls p53 activity through the regulation of PML SUMOylation.

Keywords: CACUL1; PML; SUMO; Ubiquitin; p53.

MeSH terms

  • Cell Line, Tumor
  • Cell Nucleus / metabolism
  • Cullin Proteins / metabolism*
  • HEK293 Cells
  • Humans
  • Neoplasms / metabolism
  • Promyelocytic Leukemia Protein / metabolism*
  • Protein Interaction Maps
  • Protein Processing, Post-Translational*
  • Small Ubiquitin-Related Modifier Proteins / metabolism
  • Sumoylation
  • Tumor Suppressor Protein p53 / metabolism*
  • Ubiquitin-Conjugating Enzymes / metabolism

Substances

  • CACUL1 protein, human
  • Cullin Proteins
  • Promyelocytic Leukemia Protein
  • Small Ubiquitin-Related Modifier Proteins
  • Tumor Suppressor Protein p53
  • PML protein, human
  • Ubiquitin-Conjugating Enzymes
  • ubiquitin-conjugating enzyme UBC9